Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 13 to 19 of 19 entries
Sorted by: Best Match Show Resources per page
[No title available]

Frontiers in cellular neuroscience

Bogetofte H, Jensen P, Ryding M, Schmidt SI, Okarmus J, Ritter L, Worm CS, Hohnholt MC, Azevedo C, Roybon L, Bak LK, Waagepetersen H, Ryan BJ, Wade-Martins R, Larsen MR, Meyer M.
PMID: 31333417
Front Cell Neurosci. 2019 Jul 05;13:297. doi: 10.3389/fncel.2019.00297. eCollection 2019.

The protein parkin, encoded by the

Cite
Bogetofte H, Jensen P, Ryding M, et al. . Front Cell Neurosci. 2019;13:297doi: 10.3389/fncel.2019.00297.
Bogetofte, H., Jensen, P., Ryding, M., Schmidt, S. I., Okarmus, J., Ritter, L., Worm, C. S., Hohnholt, M. C., Azevedo, C., Roybon, L., Bak, L. K., Waagepetersen, H., Ryan, B. J., Wade-Martins, R., Larsen, M. R., & Meyer, M. (2019). . Frontiers in cellular neuroscience, 13297. https://doi.org/10.3389/fncel.2019.00297
Bogetofte, Helle, et al. "." Frontiers in cellular neuroscience vol. 13 (2019): 297. doi: https://doi.org/10.3389/fncel.2019.00297
Bogetofte H, Jensen P, Ryding M, Schmidt SI, Okarmus J, Ritter L, Worm CS, Hohnholt MC, Azevedo C, Roybon L, Bak LK, Waagepetersen H, Ryan BJ, Wade-Martins R, Larsen MR, Meyer M. . Front Cell Neurosci. 2019 Jul 05;13:297. doi: 10.3389/fncel.2019.00297. eCollection 2019. PMID: 31333417; PMCID: PMC6624735.
Copy Download .nbib Format: NLM
What Is Our Understanding of the Influence of Gut Microbiota on the Pathophysiology of Parkinson's Disease?.

Frontiers in neuroscience

Hill AE, Wade-Martins R, Burnet PWJ.
PMID: 34512244
Front Neurosci. 2021 Aug 26;15:708587. doi: 10.3389/fnins.2021.708587. eCollection 2021.

Microbiota have increasingly become implicated in predisposition to human diseases, including neurodegenerative disorders such as Parkinson's disease (PD). Traditionally, a central nervous system (CNS)-centric approach to understanding PD has predominated; however, an association of the gut with PD has...

Cite
Hill AE, Wade-Martins R, Burnet PWJ. What Is Our Understanding of the Influence of Gut Microbiota on the Pathophysiology of Parkinson's Disease?. Front Neurosci. 2021;15:708587doi: 10.3389/fnins.2021.708587.
Hill, A. E., Wade-Martins, R., & Burnet, P. W. J. (2021). What Is Our Understanding of the Influence of Gut Microbiota on the Pathophysiology of Parkinson's Disease?. Frontiers in neuroscience, 15708587. https://doi.org/10.3389/fnins.2021.708587
Hill, Amaryllis E, et al. "What Is Our Understanding of the Influence of Gut Microbiota on the Pathophysiology of Parkinson's Disease?." Frontiers in neuroscience vol. 15 (2021): 708587. doi: https://doi.org/10.3389/fnins.2021.708587
Hill AE, Wade-Martins R, Burnet PWJ. What Is Our Understanding of the Influence of Gut Microbiota on the Pathophysiology of Parkinson's Disease?. Front Neurosci. 2021 Aug 26;15:708587. doi: 10.3389/fnins.2021.708587. eCollection 2021. PMID: 34512244; PMCID: PMC8432298.
Copy Download .nbib Format: NLM
"LRRK2: Autophagy and Lysosomal Activity".

Frontiers in neuroscience

Madureira M, Connor-Robson N, Wade-Martins R.
PMID: 32523507
Front Neurosci. 2020 May 25;14:498. doi: 10.3389/fnins.2020.00498. eCollection 2020.

It has been 15 years since the

Cite
Madureira M, Connor-Robson N, Wade-Martins R. "LRRK2: Autophagy and Lysosomal Activity". Front Neurosci. 2020;14:498doi: 10.3389/fnins.2020.00498.
Madureira, M., Connor-Robson, N., & Wade-Martins, R. (2020). "LRRK2: Autophagy and Lysosomal Activity". Frontiers in neuroscience, 14498. https://doi.org/10.3389/fnins.2020.00498
Madureira, Marta, et al. ""LRRK2: Autophagy and Lysosomal Activity"." Frontiers in neuroscience vol. 14 (2020): 498. doi: https://doi.org/10.3389/fnins.2020.00498
Madureira M, Connor-Robson N, Wade-Martins R. "LRRK2: Autophagy and Lysosomal Activity". Front Neurosci. 2020 May 25;14:498. doi: 10.3389/fnins.2020.00498. eCollection 2020. PMID: 32523507; PMCID: PMC7262160.
Copy Download .nbib Format: NLM
Identification of bioactive metabolites in human iPSC-derived dopaminergic neurons with PARK2 mutation: Altered mitochondrial and energy metabolism.

Stem cell reports

Okarmus J, Havelund JF, Ryding M, Schmidt SI, Bogetofte H, Heon-Roberts R, Wade-Martins R, Cowley SA, Ryan BJ, Færgeman NJ, Hyttel P, Meyer M.
PMID: 34048689
Stem Cell Reports. 2021 Jun 08;16(6):1510-1526. doi: 10.1016/j.stemcr.2021.04.022. Epub 2021 May 27.

PARK2 (parkin) mutations cause early-onset Parkinson's disease (PD). Parkin is an ubiquitin E3 ligase that participates in several cellular functions, including mitochondrial homeostasis. However, the specific metabolomic changes caused by parkin depletion remain unknown. Here, we used isogenic human...

Cite
Okarmus J, Havelund JF, Ryding M, et al. Identification of bioactive metabolites in human iPSC-derived dopaminergic neurons with PARK2 mutation: Altered mitochondrial and energy metabolism. Stem Cell Reports. 2021;16(6):1510-1526doi: 10.1016/j.stemcr.2021.04.022.
Okarmus, J., Havelund, J. F., Ryding, M., Schmidt, S. I., Bogetofte, H., Heon-Roberts, R., Wade-Martins, R., Cowley, S. A., Ryan, B. J., Færgeman, N. J., Hyttel, P., & Meyer, M. (2021). Identification of bioactive metabolites in human iPSC-derived dopaminergic neurons with PARK2 mutation: Altered mitochondrial and energy metabolism. Stem cell reports, 16(6), 1510-1526. https://doi.org/10.1016/j.stemcr.2021.04.022
Okarmus, Justyna, et al. "Identification of bioactive metabolites in human iPSC-derived dopaminergic neurons with PARK2 mutation: Altered mitochondrial and energy metabolism." Stem cell reports vol. 16,6 (2021): 1510-1526. doi: https://doi.org/10.1016/j.stemcr.2021.04.022
Okarmus J, Havelund JF, Ryding M, Schmidt SI, Bogetofte H, Heon-Roberts R, Wade-Martins R, Cowley SA, Ryan BJ, Færgeman NJ, Hyttel P, Meyer M. Identification of bioactive metabolites in human iPSC-derived dopaminergic neurons with PARK2 mutation: Altered mitochondrial and energy metabolism. Stem Cell Reports. 2021 Jun 08;16(6):1510-1526. doi: 10.1016/j.stemcr.2021.04.022. Epub 2021 May 27. PMID: 34048689; PMCID: PMC8190670.
Copy Download .nbib Format: NLM
Wild-Type, but Not Mutant N296H, Human Tau Restores Aβ-Mediated Inhibition of LTP in .

Frontiers in neuroscience

Vargas-Caballero M, Denk F, Wobst HJ, Arch E, Pegasiou CM, Oliver PL, Shipton OA, Paulsen O, Wade-Martins R.
PMID: 28484365
Front Neurosci. 2017 Apr 24;11:201. doi: 10.3389/fnins.2017.00201. eCollection 2017.

Microtubule associated protein tau (MAPT) is involved in the pathogenesis of Alzheimer's disease and many forms of frontotemporal dementia (FTD). We recently reported that Aβ-mediated inhibition of hippocampal long-term potentiation (LTP) in mice requires tau. Here, we asked whether...

Cite
Vargas-Caballero M, Denk F, Wobst HJ, et al. Wild-Type, but Not Mutant N296H, Human Tau Restores Aβ-Mediated Inhibition of LTP in . Front Neurosci. 2017;11:201doi: 10.3389/fnins.2017.00201.
Vargas-Caballero, M., Denk, F., Wobst, H. J., Arch, E., Pegasiou, C. M., Oliver, P. L., Shipton, O. A., Paulsen, O., & Wade-Martins, R. (2017). Wild-Type, but Not Mutant N296H, Human Tau Restores Aβ-Mediated Inhibition of LTP in . Frontiers in neuroscience, 11201. https://doi.org/10.3389/fnins.2017.00201
Vargas-Caballero, Mariana, et al. "Wild-Type, but Not Mutant N296H, Human Tau Restores Aβ-Mediated Inhibition of LTP in ." Frontiers in neuroscience vol. 11 (2017): 201. doi: https://doi.org/10.3389/fnins.2017.00201
Vargas-Caballero M, Denk F, Wobst HJ, Arch E, Pegasiou CM, Oliver PL, Shipton OA, Paulsen O, Wade-Martins R. Wild-Type, but Not Mutant N296H, Human Tau Restores Aβ-Mediated Inhibition of LTP in . Front Neurosci. 2017 Apr 24;11:201. doi: 10.3389/fnins.2017.00201. eCollection 2017. PMID: 28484365; PMCID: PMC5401872.
Copy Download .nbib Format: NLM
Episomal Nonviral Gene Therapy Vectors Slow Progression of Atherosclerosis in a Model of Familial Hypercholesterolemia.

Molecular therapy. Nucleic acids

Kerr AG, Tam LC, Hale AB, Cioroch M, Douglas G, Channon KM, Wade-Martins R.
PMID: 27824334
Mol Ther Nucleic Acids. 2016 Nov 08;5(11):e383. doi: 10.1038/mtna.2016.86.

Familial hypercholesterolemia (FH) is a life-threatening genetic disorder characterized by elevated levels of plasma low-density lipoprotein cholesterol (LDL-cholesterol). Current attempts at gene therapy for FH have been limited by the use of strong heterologous promoters which lack genomic DNA...

Cite
Kerr AG, Tam LC, Hale AB, et al. Episomal Nonviral Gene Therapy Vectors Slow Progression of Atherosclerosis in a Model of Familial Hypercholesterolemia. Mol Ther Nucleic Acids. 2016;5(11):e383doi: 10.1038/mtna.2016.86.
Kerr, A. G., Tam, L. C., Hale, A. B., Cioroch, M., Douglas, G., Channon, K. M., & Wade-Martins, R. (2016). Episomal Nonviral Gene Therapy Vectors Slow Progression of Atherosclerosis in a Model of Familial Hypercholesterolemia. Molecular therapy. Nucleic acids, 5(11), e383. https://doi.org/10.1038/mtna.2016.86
Kerr, Alastair G, et al. "Episomal Nonviral Gene Therapy Vectors Slow Progression of Atherosclerosis in a Model of Familial Hypercholesterolemia." Molecular therapy. Nucleic acids vol. 5,11 (2016): e383. doi: https://doi.org/10.1038/mtna.2016.86
Kerr AG, Tam LC, Hale AB, Cioroch M, Douglas G, Channon KM, Wade-Martins R. Episomal Nonviral Gene Therapy Vectors Slow Progression of Atherosclerosis in a Model of Familial Hypercholesterolemia. Mol Ther Nucleic Acids. 2016 Nov 08;5(11):e383. doi: 10.1038/mtna.2016.86. PMID: 27824334; PMCID: PMC5155321.
Copy Download .nbib Format: NLM
Potential Metabolomic Linkage in Blood between Parkinson's Disease and Traumatic Brain Injury.

Metabolites

Fiandaca MS, Gross TJ, Johnson TM, Hu MT, Evetts S, Wade-Martins R, Merchant-Borna K, Bazarian J, Cheema AK, Mapstone M, Federoff HJ.
PMID: 30205491
Metabolites. 2018 Sep 07;8(3). doi: 10.3390/metabo8030050.

The etiologic basis for sporadic forms of neurodegenerative diseases has been elusive but likely represents the product of genetic predisposition and various environmental factors. Specific gene-environment interactions have become more salient owing, in part, to the elucidation of epigenetic...

Cite
Fiandaca MS, Gross TJ, Johnson TM, et al. Potential Metabolomic Linkage in Blood between Parkinson's Disease and Traumatic Brain Injury. Metabolites. 2018;8(3)doi: 10.3390/metabo8030050.
Fiandaca, M. S., Gross, T. J., Johnson, T. M., Hu, M. T., Evetts, S., Wade-Martins, R., Merchant-Borna, K., Bazarian, J., Cheema, A. K., Mapstone, M., & Federoff, H. J. (2018). Potential Metabolomic Linkage in Blood between Parkinson's Disease and Traumatic Brain Injury. Metabolites, 8(3), . https://doi.org/10.3390/metabo8030050
Fiandaca, Massimo S, et al. "Potential Metabolomic Linkage in Blood between Parkinson's Disease and Traumatic Brain Injury." Metabolites vol. 8,3 (2018). doi: https://doi.org/10.3390/metabo8030050
Fiandaca MS, Gross TJ, Johnson TM, Hu MT, Evetts S, Wade-Martins R, Merchant-Borna K, Bazarian J, Cheema AK, Mapstone M, Federoff HJ. Potential Metabolomic Linkage in Blood between Parkinson's Disease and Traumatic Brain Injury. Metabolites. 2018 Sep 07;8(3). doi: 10.3390/metabo8030050. PMID: 30205491; PMCID: PMC6161135.
Copy Download .nbib Format: NLM
Showing 13 to 19 of 19 entries